Pregnancy Associated Breast Cancer (PABC): Report from a gestational cancer registry from a tertiary cancer care centre, India

LATEST ARTICLES
SEARCH INDEX
SUGGEST ARTICLE
THE OSI COLLECTIONS
AUDIOGRAM SERIES
ABOUT THE OSI
2020 SUMMARY

OSI STATISTICS

Open access articles:
837
Annotations added:
3
Countries represented:
106
No. of contributors:
12
Bookmarks made:
21

Pregnancy Associated Breast Cancer (PABC): Report from a gestational cancer registry from a tertiary cancer care centre, India


JournalThe Breast
Article typeJournal research article – Clinical research
Publication date – Feb – 2021
Authors – Jyoti bajpai, Vijay Simha, T.S. Shylasree, Rajeev Sarin, Reema Pathak, Palak Popat, Smruti Mokal, Sonal Dandekar, Jaya Ghosh, Neeta Nair, Seema Gulia, Sushmita Rath, Shalaka Joshi,Tabassum Wadasadawala, Tanuja Sheth, Vani Parmar, R.A. Badwe, Sudeep Gupta
Keywordsantepartum, Gestational, postpartum, Pregnancy Associated Breast Cancer (PABC), Registry, trimester
Open access – Yes
SpecialityGeneral surgery, Obstetrics and Gynaecology, Plastic surgery, Surgical oncology
World region Southern Asia
Country: India
Language – English
Submitted to the One Surgery Index on February 25, 2021 at 9:19 am
Abstract:

Background
Pregnancy associated breast cancer (PABC) is a rare entity and defined as breast cancer diagnosed during pregnancy or one-year post-partum. There is sparse data especially from low and middle-income countries (LMIC) and merits exploration.

Methods
The study (2013 -2020) evaluated demographics, treatment patterns and outcomes of PABC.

Results
There were 104 patients, median age of 31 years; 43 (41%) had triple-negative disease, 31(29.8%) had hormone-receptor (HR) positive and HER2 negative, 14 (13.5%) had HER2-positive and HR negative and 16(15.4%) had triple positive disease. 101(97%) had IDC grade III tumors and 74% had delayed diagnosis. 72% presented with early stage (24, EBC) or locally advanced breast cancer (53, LABC) and received either neoadjuvant (n=49) or adjuvant (n=26) chemotherapy and surgery. Trastuzumab, tamoxifen, and radiotherapy were administered post-delivery. At a median follow up of 27 (IQR:19-35) months, the estimated 3-year event-free survival (EFS) for EBC and LABC was 82% (95% CI: 65.2 – 100) and 56% (95% CI: 42 – 75.6%) and for metastatic 24% (95% CI: 10.1% – 58.5%) respectively.

Of the 104 patients, 34 were diagnosed antepartum (AP) and 15 had termination, 2 had preterm and 16 had full-term deliveries(FTDs). Among postpartum cohort (n=70), 2 had termination, 1 had preterm, 67 had FTDs. 83(including 17 from AP) children from both cohorts were experiencing normal milestones.

Conclusion
Data from the first Indian PABC registry showed that the majority had delayed diagnosis and aggressive features(TNBC, higher grade). Treatment was feasible in majority and stage matched outcomes were comparable to non-PABCs.

OSI Number – 20944

Public annotations on this article:
No public annotations yet